HRP20170194T1 - Lxr modulatori - Google Patents
Lxr modulatori Download PDFInfo
- Publication number
- HRP20170194T1 HRP20170194T1 HRP20170194TT HRP20170194T HRP20170194T1 HR P20170194 T1 HRP20170194 T1 HR P20170194T1 HR P20170194T T HRP20170194T T HR P20170194TT HR P20170194 T HRP20170194 T HR P20170194T HR P20170194 T1 HRP20170194 T1 HR P20170194T1
- Authority
- HR
- Croatia
- Prior art keywords
- substance
- pharmaceutically acceptable
- acceptable salt
- isotopically labeled
- propan
- Prior art date
Links
- 239000000126 substance Substances 0.000 claims 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- PCAWBEDTJCPNOG-UHFFFAOYSA-N 2-[1-[2-chloro-4-[3-fluoro-4-(hydroxymethyl)-5-methylsulfonylphenyl]phenyl]-2-[2-(2,6-dichlorophenyl)propan-2-yl]imidazol-4-yl]propan-2-ol Chemical compound N=1C(C(C)(O)C)=CN(C=2C(=CC(=CC=2)C=2C=C(C(CO)=C(F)C=2)S(C)(=O)=O)Cl)C=1C(C)(C)C1=C(Cl)C=CC=C1Cl PCAWBEDTJCPNOG-UHFFFAOYSA-N 0.000 claims 1
- HNAJDMYOTDNOBK-UHFFFAOYSA-N 2-[2-[2-(2,6-dichlorophenyl)propan-2-yl]-1-[2-fluoro-4-[3-fluoro-4-(hydroxymethyl)-5-methylsulfonylphenyl]phenyl]imidazol-4-yl]propan-2-ol Chemical compound N=1C(C(C)(O)C)=CN(C=2C(=CC(=CC=2)C=2C=C(C(CO)=C(F)C=2)S(C)(=O)=O)F)C=1C(C)(C)C1=C(Cl)C=CC=C1Cl HNAJDMYOTDNOBK-UHFFFAOYSA-N 0.000 claims 1
- LODWYHGIAQYCAL-UHFFFAOYSA-N 2-[2-[2-(2,6-dichlorophenyl)propan-2-yl]-1-[4-[3-fluoro-4-(hydroxymethyl)-5-methylsulfonylphenyl]phenyl]imidazol-4-yl]propan-2-ol Chemical compound N=1C(C(C)(O)C)=CN(C=2C=CC(=CC=2)C=2C=C(C(CO)=C(F)C=2)S(C)(=O)=O)C=1C(C)(C)C1=C(Cl)C=CC=C1Cl LODWYHGIAQYCAL-UHFFFAOYSA-N 0.000 claims 1
- IQFPWMNABYUYJC-UHFFFAOYSA-N 2-[2-[2-(2-chloro-3-fluorophenyl)propan-2-yl]-1-[4-[3-fluoro-4-(hydroxymethyl)-5-methylsulfonylphenyl]phenyl]imidazol-4-yl]propan-2-ol Chemical compound N=1C(C(C)(O)C)=CN(C=2C=CC(=CC=2)C=2C=C(C(CO)=C(F)C=2)S(C)(=O)=O)C=1C(C)(C)C1=CC=CC(F)=C1Cl IQFPWMNABYUYJC-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000034493 Mucous membrane disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000037365 barrier function of the epidermis Effects 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Tvar, izotopno-obilježena tvar ili njena farmaceutski prihvatljiva sol, odabrana između:
[image]
2. Tvar, izotopno-obilježena tvar ili njena farmaceutski prihvatljiva sol, iz patentnog zahtjeva 1 odabrana između:
[image]
3. Tvar, izotopno-obilježena tvar ili njena farmaceutski prihvatljiva sol, iz patentnog zahtjeva 1 odabrana između:
[image]
4. Tvar, izotopno-obilježena tvar ili njena farmaceutski prihvatljiva sol, iz patentnog zahtjeva 1 odabrana između:
[image]
5. Tvar, izotopno-obilježena tvar ili njena farmaceutski prihvatljiva sol iz patentnog zahtjeva 4, koja je 2-(1-(3-kloro-3’-fluoro-4’-(hidroksimetil)-5’-(metilsulfonil)bifenil-4-il)-2-(2-(2,6-diklorofenil)propan-2-il)-1H-imidazol-4-il)propan-2-ol.
6. Tvar, izotopno-obilježena tvar ili njena farmaceutski prihvatljiva sol iz patentnog zahtjeva 4, koja je 2-(2-(2-(2-kloro-3-fluorofenil)propan-2-il)-1-(3’-fluoro-4’-(hidroksimetil)-5’-(metilsulfonil)bifenil-4-il)-1H-imidazol-4-il)propan-2-ol.
7. Tvar, izotopno-obilježena tvar ili njena farmaceutski prihvatljiva sol iz patentnog zahtjeva 4, koja je 2-(2-(2-(2,6-diklorofenil)propan-2-il)-1-(3’-fluoro-4’-(hidroksimetil)-5’-(metilsulfonil)bifenil-4-il)-1H-imidazol-4-il)propan-2-ol.
8. Tvar, izotopno-obilježena tvar ili njena farmaceutski prihvatljiva sol iz patentnog zahtjeva 4, koja je 2-(2-(2-(2,6-diklorofenil)propan-2-il)-1-(3,3’-difluoro-4’-(hidroksimetil)-5’-(metilsulfonil)bifenil-4-il)-1H-imidazol-4-il)propan-2-ol.
9. Tvar, izotopno-obilježena tvar ili njena farmaceutski prihvatljiva sol iz patentnog zahtjeva 4, koja je 2-{2-[1-(2,6-diklorofenil)etil]-1-[3,3’-difluoro-4’-(hidroksimetil)-5’-(metilsulfonil)bifenil-4-il]-1-H-imidazol-4-il}propan-2-ol.
10. Sastav koji sadrži tvar iz bilo kojeg od patentnih zahtjeva 1 do 9, izotopno-obilježenu tvar ili njenu farmaceutski prihvatljivu sol i jedan ili više farmaceutski prihvatljivih nosača.
11. Tvar u skladu s bilo kojim od patentnih zahtjeva 1 do 9, izotopno-obilježena tvar, ili njena farmaceutski prihvatljiva sol, ili sastav u skladu s patentnim zahtjevom 10, za uporabu u liječenju bolesti ili poremećaja odabranih između ateroskleroze, inzulinske rezistencije, osteoartritisa, moždanog udara, hiperglikemije, dislipidemije, psorijaze, starošću i izlaganjem UV-zrakama uzrokovanog boranja kože, dijabetesa, raka, Alzheimerove bolesti, upale, imunoloških poremećaja, poremećaja lipida, pretilosti, makularne degeneracije, stanja karakteriziranih narušenom funkcijom epidermalne barijere, stanjima poremećene diferencijacije ili pretjerane proliferacije epidermisa ili mukozne membrane, ili kardiovaskularnih poremećaja.
12. Tvar ili sastav za uporabu iz patentnog zahtjeva 11 pri čemu je bolest ili poremećaj ateroskleroza, dijabetes, Alzheimerova bolest ili dislipidemija.
13. Tvar ili sastav za uporabu iz patentnog zahtjeva 11 pri čemu je bolest ili poremećaj ateroskleroza.
14. Tvar ili sastav za uporabu iz patentnog zahtjeva 11 pri čemu je bolest ili poremećaj dijabetes.
15. Tvar ili sastav za uporabu iz patentnog zahtjeva 11 pri čemu je bolest ili poremećaj Alzheimerova bolest.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18173609P | 2009-05-28 | 2009-05-28 | |
PCT/US2010/036211 WO2010138598A2 (en) | 2009-05-28 | 2010-05-26 | Lxr modulators |
EP10721902.4A EP2435410B1 (en) | 2009-05-28 | 2010-05-26 | Lxr modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170194T1 true HRP20170194T1 (hr) | 2017-05-19 |
Family
ID=43223342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170194TT HRP20170194T1 (hr) | 2009-05-28 | 2017-02-06 | Lxr modulatori |
Country Status (30)
Country | Link |
---|---|
US (4) | US8618154B2 (hr) |
EP (1) | EP2435410B1 (hr) |
JP (1) | JP5625050B2 (hr) |
KR (1) | KR101676704B1 (hr) |
CN (1) | CN102648184B (hr) |
AR (1) | AR078049A1 (hr) |
AU (1) | AU2010254082B2 (hr) |
BR (1) | BRPI1013259B8 (hr) |
CA (1) | CA2761934C (hr) |
CL (1) | CL2011002972A1 (hr) |
CO (1) | CO6470826A2 (hr) |
CY (1) | CY1119407T1 (hr) |
DK (1) | DK2435410T3 (hr) |
EA (1) | EA019960B1 (hr) |
ES (1) | ES2620451T3 (hr) |
HR (1) | HRP20170194T1 (hr) |
IL (1) | IL216176A (hr) |
LT (1) | LT2435410T (hr) |
MX (1) | MX2011012559A (hr) |
MY (1) | MY153958A (hr) |
NZ (1) | NZ596330A (hr) |
PE (1) | PE20120797A1 (hr) |
PL (1) | PL2435410T3 (hr) |
PT (1) | PT2435410T (hr) |
SG (1) | SG176247A1 (hr) |
SI (1) | SI2435410T1 (hr) |
TN (1) | TN2011000585A1 (hr) |
TW (1) | TWI488844B (hr) |
WO (1) | WO2010138598A2 (hr) |
ZA (1) | ZA201108181B (hr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011012559A (es) * | 2009-05-28 | 2012-06-08 | Exelixis Patent Co Llc | Moduladores de lxr. |
AR088728A1 (es) * | 2011-03-25 | 2014-07-02 | Bristol Myers Squibb Co | Moduladores de lxr como prodroga de imidazol |
EP2820013B9 (en) | 2012-03-02 | 2019-01-09 | Ralexar Therapeutics, Inc. | Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions |
CA3211094A1 (en) * | 2012-08-13 | 2014-02-20 | The Rockefeller University | Treatment and diagnosis of melanoma |
CN105188380B (zh) | 2013-03-15 | 2017-08-15 | 百时美施贵宝公司 | Lxr调节剂 |
JP6442475B2 (ja) * | 2013-03-15 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Lxr調節因子 |
DK3041835T3 (da) | 2013-09-04 | 2020-07-13 | Ellora Therapeutics Inc | Modulatorer af lever-X-receptorer (LXR) |
MX2016002930A (es) | 2013-09-04 | 2016-12-02 | Ralexar Therapeutics Inc | Moduladores del receptor x hepatico (lxr). |
EP3091970B1 (en) | 2014-01-10 | 2020-10-28 | Rgenix, Inc. | Lxr agonists and uses thereof |
KR101815734B1 (ko) | 2015-05-29 | 2018-01-05 | 가톨릭대학교 산학협력단 | miR-7, miR-18a 또는 miR-18b를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
EP3402477A4 (en) | 2016-01-11 | 2019-08-21 | The Rockefeller University | METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS |
US11214536B2 (en) | 2017-11-21 | 2022-01-04 | Inspirna, Inc. | Polymorphs and uses thereof |
CN114126618A (zh) | 2019-07-15 | 2022-03-01 | 诺华股份有限公司 | 用肝脏x受体激动剂治疗睑板腺功能障碍的方法 |
CN110305141B (zh) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用 |
CN114728875A (zh) | 2019-12-13 | 2022-07-08 | 因思博纳公司 | 金属盐及其用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
WO1984002131A1 (en) | 1982-11-22 | 1984-06-07 | Sandoz Ag | Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
DE69232537T2 (de) | 1991-09-17 | 2002-10-24 | Salk Inst For Biolog Studies L | Rezeptoren der steroid/thyroid superfamilie von rezeptoren |
EP1019059A4 (en) | 1997-01-24 | 2004-01-14 | Univ California | USE OF FXR, PPAR-ALPHA AND LXR-ALPHA ACTIVATORS TO RESTORE THE BARRIER FUNCTION, TO PROMOTE EPIDERMIS DIFFERENTIATION, AND TO PROLIFERATE |
EP1115853A2 (en) | 1998-09-23 | 2001-07-18 | Ludmila Solomin | Analysis of ligand activated nuclear receptors in vivo |
EP1140079B1 (en) | 1998-12-23 | 2009-06-03 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
ATE330632T1 (de) | 1999-03-26 | 2006-07-15 | Hope City | Selektion von fxr-rezeptormodulatoren |
IL147022A0 (en) | 1999-06-18 | 2002-08-14 | Cv Therapeutics Inc | Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1 |
AU2001262984A1 (en) | 2000-05-03 | 2001-11-12 | Tularik, Inc. | Treatment of hypertriglyceridemia and other conditions using lxr modulators |
US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
US7482366B2 (en) * | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
WO2004011446A1 (en) * | 2002-07-26 | 2004-02-05 | Bayer Pharmaceuticals Corporation | Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics |
US7109227B2 (en) * | 2002-08-26 | 2006-09-19 | National Health Research Institutes | Imidazolamino compounds |
WO2004106307A2 (fr) * | 2003-05-27 | 2004-12-09 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament |
WO2005047266A1 (en) * | 2003-11-14 | 2005-05-26 | Lorus Therapeutics Inc. | Aryl imidazoles and their use as anti-cancer agents |
BRPI0507632A (pt) * | 2004-02-11 | 2007-07-03 | Irm Llc | compostos e composições como moduladores de lxr |
SG162803A1 (en) * | 2005-06-27 | 2010-07-29 | Exelixis Inc | Imidazole based lxr modulators |
JP5237799B2 (ja) * | 2005-06-27 | 2013-07-17 | エグゼリクシス パテント カンパニー エルエルシー | ピラゾールベースのlxrモジュレーター |
JP5399262B2 (ja) * | 2006-12-08 | 2014-01-29 | エグゼリクシス パテント カンパニー エルエルシー | Lxrおよびfxrのモジュレーター |
MX2011012559A (es) * | 2009-05-28 | 2012-06-08 | Exelixis Patent Co Llc | Moduladores de lxr. |
-
2010
- 2010-05-26 MX MX2011012559A patent/MX2011012559A/es active IP Right Grant
- 2010-05-26 PT PT107219024T patent/PT2435410T/pt unknown
- 2010-05-26 US US13/319,937 patent/US8618154B2/en active Active
- 2010-05-26 AU AU2010254082A patent/AU2010254082B2/en active Active
- 2010-05-26 CN CN201080033601.2A patent/CN102648184B/zh active Active
- 2010-05-26 LT LTEP10721902.4T patent/LT2435410T/lt unknown
- 2010-05-26 JP JP2012513215A patent/JP5625050B2/ja active Active
- 2010-05-26 SG SG2011087459A patent/SG176247A1/en unknown
- 2010-05-26 PE PE2011002005A patent/PE20120797A1/es active IP Right Grant
- 2010-05-26 PL PL10721902T patent/PL2435410T3/pl unknown
- 2010-05-26 NZ NZ596330A patent/NZ596330A/xx unknown
- 2010-05-26 KR KR1020117031397A patent/KR101676704B1/ko active IP Right Grant
- 2010-05-26 WO PCT/US2010/036211 patent/WO2010138598A2/en active Application Filing
- 2010-05-26 CA CA2761934A patent/CA2761934C/en active Active
- 2010-05-26 SI SI201031427A patent/SI2435410T1/sl unknown
- 2010-05-26 DK DK10721902.4T patent/DK2435410T3/da active
- 2010-05-26 EA EA201171488A patent/EA019960B1/ru not_active IP Right Cessation
- 2010-05-26 ES ES10721902.4T patent/ES2620451T3/es active Active
- 2010-05-26 BR BRPI1013259A patent/BRPI1013259B8/pt active IP Right Grant
- 2010-05-26 MY MYPI2011006278A patent/MY153958A/en unknown
- 2010-05-26 EP EP10721902.4A patent/EP2435410B1/en active Active
- 2010-05-28 TW TW099117252A patent/TWI488844B/zh active
- 2010-05-28 AR ARP100101870A patent/AR078049A1/es not_active Application Discontinuation
-
2011
- 2011-11-07 IL IL216176A patent/IL216176A/en active IP Right Grant
- 2011-11-08 ZA ZA2011/08181A patent/ZA201108181B/en unknown
- 2011-11-16 TN TNP2011000585A patent/TN2011000585A1/en unknown
- 2011-11-24 CL CL2011002972A patent/CL2011002972A1/es unknown
- 2011-11-25 CO CO11161736A patent/CO6470826A2/es active IP Right Grant
-
2013
- 2013-11-21 US US14/085,926 patent/US20140163081A1/en not_active Abandoned
-
2015
- 2015-05-04 US US14/703,247 patent/US20150299136A1/en not_active Abandoned
-
2016
- 2016-06-07 US US15/175,425 patent/US20160280661A1/en not_active Abandoned
-
2017
- 2017-02-06 HR HRP20170194TT patent/HRP20170194T1/hr unknown
- 2017-04-05 CY CY20171100403T patent/CY1119407T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170194T1 (hr) | Lxr modulatori | |
Karpiński | Selected medicines used in iontophoresis | |
EA200802208A1 (ru) | Применение флибансерина для лечения расстройств полового влечения в постклимактерический период | |
JP2012528180A5 (hr) | ||
BRPI0721116A2 (pt) | Aparelho terapêutico para aliviar obstrução da via aérea superior de um paciente, e, métodos para aplicar uma força para aliviar obstrução da via aérea superior de um paciente e para reduzir ronco | |
BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
BRPI0811436A2 (pt) | Composto, uso de um composto, composição farmacêutica, e, metódos para a terapia da dor em um animal de sangue quente, para a terapia da bexiga super ativa em um animal de sangue quente, e para preparar um composto. | |
BR112014016165A2 (pt) | compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido | |
CL2012001673A1 (es) | Compuestos derivados de benzamida sustituidos, como moduladores de taar; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de la depresión, trastornos de ansiedad, trastorno bipolar, esquizofrenia, epilepsia, migraña, enfermedad de alzheimer, trastornos metabolicos, entre otras. | |
BRPI0820800A2 (pt) | Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente | |
WO2009053741A3 (en) | Novel formulation | |
BRPI0809260A2 (pt) | Dispositivo para a assistência médica de um paciente em uma emergência | |
CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
SMT201300095B (it) | Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia | |
DK2276485T3 (da) | Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom | |
ECSP055985A (es) | Derivados de ácido 3-metil-2-(3-(2-fenil-oxazol-4-ilmetoxi)-ciclohexanocarbonil-aminobutírico y compuestos relacionados como moduladores de ppar para el tratamiento de diabetes de tipo 2 y aterosclerosis | |
EA200901112A1 (ru) | Жидкие композиции, образующие дермальные пленки, для введения лекарственных препаратов в кожу | |
BRPI0914902A2 (pt) | composição farmacêutica e método para tratamento de mal de parkinson | |
AR082312A1 (es) | Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos | |
BR112014011981A8 (pt) | Formulações farmacêuticas sólidas orais, seus processos de preparação e usos | |
BRPI0520258A2 (pt) | uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina | |
DOP2010000300A (es) | Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre | |
BRPI0921557A2 (pt) | bacteriófago filamentoso, primeiro e segundo bacteriófago filamentoso para o uso no tratamento do mal de parkinson, composição farmacêutica, e , método para tratar um paciente | |
BRPI0913854A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para o tratamento, a prevenção ou o alívio de uma doença ou um distúrbio ou uma condição de um organismo de animal vivente. | |
FR2918282B1 (fr) | Medicament pour le traitement de la maladie de parkinson |